C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
1.470
-0.070 (-4.55%)
At close: Jun 5, 2025, 4:00 PM
1.470
0.00 (0.00%)
After-hours: Jun 5, 2025, 4:17 PM EDT

C4 Therapeutics Statistics

Total Valuation

C4 Therapeutics has a market cap or net worth of $104.03 million. The enterprise value is -$60.99 million.

Market Cap 104.03M
Enterprise Value -60.99M

Important Dates

The next estimated earnings date is Thursday, July 31, 2025, before market open.

Earnings Date Jul 31, 2025
Ex-Dividend Date n/a

Share Statistics

C4 Therapeutics has 71.01 million shares outstanding. The number of shares has increased by 28.41% in one year.

Current Share Class 71.01M
Shares Outstanding 71.01M
Shares Change (YoY) +28.41%
Shares Change (QoQ) +0.32%
Owned by Insiders (%) 3.65%
Owned by Institutions (%) 72.72%
Float 49.73M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 2.71
Forward PS 8.91
PB Ratio 0.56
P/TBV Ratio 0.56
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 5.70, with a Debt / Equity ratio of 0.33.

Current Ratio 5.70
Quick Ratio 5.47
Debt / Equity 0.33
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -45.55% and return on invested capital (ROIC) is -24.80%.

Return on Equity (ROE) -45.55%
Return on Assets (ROA) -20.30%
Return on Invested Capital (ROIC) -24.80%
Return on Capital Employed (ROCE) -41.82%
Revenue Per Employee $361,664
Profits Per Employee -$938,882
Employee Count 110
Asset Turnover 0.11
Inventory Turnover n/a

Taxes

In the past 12 months, C4 Therapeutics has paid $131,000 in taxes.

Income Tax 131,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -70.20% in the last 52 weeks. The beta is 2.94, so C4 Therapeutics's price volatility has been higher than the market average.

Beta (5Y) 2.94
52-Week Price Change -70.20%
50-Day Moving Average 1.45
200-Day Moving Average 3.75
Relative Strength Index (RSI) 50.53
Average Volume (20 Days) 943,909

Short Selling Information

The latest short interest is 6.36 million, so 8.95% of the outstanding shares have been sold short.

Short Interest 6.36M
Short Previous Month 6.41M
Short % of Shares Out 8.95%
Short % of Float 12.78%
Short Ratio (days to cover) 5.08

Income Statement

In the last 12 months, C4 Therapeutics had revenue of $39.78 million and -$103.28 million in losses. Loss per share was -$1.48.

Revenue 39.78M
Gross Profit -75.39M
Operating Income -116.56M
Pretax Income -106.59M
Net Income -103.28M
EBITDA -114.73M
EBIT -116.56M
Loss Per Share -$1.48
Full Income Statement

Balance Sheet

The company has $215.09 million in cash and $64.37 million in debt, giving a net cash position of $170.34 million or $2.40 per share.

Cash & Cash Equivalents 215.09M
Total Debt 64.37M
Net Cash 170.34M
Net Cash Per Share $2.40
Equity (Book Value) 195.14M
Book Value Per Share 2.75
Working Capital 191.72M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$80.32 million and capital expenditures -$180,000, giving a free cash flow of -$80.50 million.

Operating Cash Flow -80.32M
Capital Expenditures -180,000
Free Cash Flow -80.50M
FCF Per Share -$1.13
Full Cash Flow Statement

Margins

Gross margin is -189.51%, with operating and profit margins of -292.99% and -259.60%.

Gross Margin -189.51%
Operating Margin -292.99%
Pretax Margin -259.27%
Profit Margin -259.60%
EBITDA Margin -288.40%
EBIT Margin -292.99%
FCF Margin n/a

Dividends & Yields

C4 Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -28.41%
Shareholder Yield -28.41%
Earnings Yield -94.45%
FCF Yield -73.62%

Analyst Forecast

The average price target for C4 Therapeutics is $12.00, which is 719.11% higher than the current price. The consensus rating is "Buy".

Price Target $12.00
Price Target Difference 719.11%
Analyst Consensus Buy
Analyst Count 3
Revenue Growth Forecast (5Y) 114.32%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

C4 Therapeutics has an Altman Z-Score of -1.57 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -1.57
Piotroski F-Score 4